Please amend the subject application as follows:

In the claims:

Please cancel claims 102-120 without disclaimer or prejudice to applicants' right to pursue the subject matter of these claims in later-filed application. Please add new claims 121-134 as follows:

--121. (New) A composition which comprises:

a) a conjugate of i) a ganglioside derivative which comprises an unaltered oligosaccharide part and an altered ceramide portion comprising a sphingosine base, to ii) an immunogenic protein-based carrier;

b) a saponin derivable from the bark of a Quillaja saponaria Molina tree; and

c) a pharmaceutically acceptable carrier;

the relative amounts of such conjugate and such saponin being effective to stimulate or enhance antibody production in a subject,

wherein the ganglioside derivative is a derivative of a ganglioside selected from the group consisting of GM2, GM3, GD2, GD3, GD3 lactone, O-acetyl GD3 and GT3; and

wherein the immunogenic protein-based carrier is derived from a protein selected from the group consisting of malaria T-cell epitope, an outer membrane protein of Neisseria meningitidis, cationized bovine serum albumin, Keyhole Limpet Hemocyanin, polylysine and human serum albumin;

wherein in the conjugate the ganglioside derivative is conjugated to the immunogenic protein-based carrier

through a C-4 carbon of the sphingosine base of the ceramide portion of the ganglioside derivative. --

110
--122. (New) The composition of claim 121, wherein the saponin derivable from the bark of a Quillaja saponaria Molina tree is QS-21.--

111
--123. (New) The composition of claim 121, wherein the ganglioside derivative is a derivative of GM2 or GD2.

112
--124. (New) The composition of claim 121, wherein the ganglioside derivative is a derivative of GM2.--

113
--125. (New) The composition of claim 121, wherein the ganglioside derivative is a derivative of GD2.--

114
--126. (New) The composition of claim 121, wherein the amount of the conjugate is an amount between about 1 μg and about 200 μg.--

115
--127. (New) The composition of claim 121, wherein the amount of the conjugate is an amount between about 50 μg and about 90 μg.--

116
--128. (New) The composition of claim 121, wherein the amount of the conjugate is about 70 μg.--

117
--129. (New) The composition of claim 121, wherein the amount of the conjugate is an amount between about 1 μg and about 10 μg.--

--130. (New) The composition of claim 121, wherein the amount of the conjugate is about 7 μg.--

--131. (New) The composition of claim 121, wherein the amount of the saponin is an amount between about 10 μg and about 200 μg.--

--132. (New) The composition of claim 121, wherein the amount of the saponin is about 100 μg.--

--133. (New) The composition of claim 121, wherein the amount of the saponin is about 200 μg.--

--134. (New) The composition of claim 121, wherein the molar ratio of the ganglioside derivative to the immunogenic protein-based carrier is from about 200 to about 1400.--

REMARKS

Claims 102-120 are pending in the subject application. Applicants have hereinabove canceled claims 102-120 without prejudice or disclaimer to their right to pursue the subject matter of these claims in a later-filed application and added new claims 121-134. Support for these claims may be found inter alia in the specification as follows: claim 121: page 11, lines 3-27; page 32, lines 1-27; page 76, lines 19-21; page 11, lines 22-28; page 12, lines 23-26; page 19, lines 10-13; page 41, line 16; claim 122: page 12, lines 15-16; claims 123-125: page 12, lines 28-31; claims 126-130: page 13, lines 8-26; claims 131-133: page 14, lines 1-5;